Aytu Biopharma (AYTU) Other Accumulated Expenses (2019 - 2026)

Aytu Biopharma (AYTU) has 8 years of Other Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 18.99% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 18.99% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, down 78.86% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $2.2 million, down from $2.9 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for AYTU reached as high as $9.1 million in Q1 2024 and fell as low as $1.8 million in Q1 2025.
• Historically, Other Accumulated Expenses has averaged $4.9 million across 5 years, with a median of $3.5 million in 2022.
• Across the five-year window, Other Accumulated Expenses soared 214.18% in 2024 and sank 79.79% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $7.8 million in 2022, then plunged by 67.7% to $2.5 million in 2023, then surged by 180.95% to $7.1 million in 2024, then tumbled by 58.88% to $2.9 million in 2025, then decreased by 24.77% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $2.2 million in Q1 2026, $2.9 million in Q4 2025, and $2.0 million in Q3 2025.